Amidst tariff tensions with the US, Europe has created a major opportunity for the Indian pharmaceutical industry. The CDSCO has granted approval to three Indian companies to export APIs to the European Union. This will enhance the competitiveness of Indian generic medicines, boost exports, and strengthen India’s share in the European market. However, companies will have to consistently adhere to strict quality standards.
India’s drug manufacturers have been given access to Europe’s market owing to the tariff issues between Europe and the USA. Written approval from CDSCO has been granted to some Indian firms for exporting their active pharmaceutical ingredients (APIs) to the European Union (EU). APIs are nothing but those chemicals which are needed for manufacturing medicines such as cancer, antibiotics, and other drugs.
According to CDSCO, all the companies which have obtained written permission have to strictly maintain the quality standards. In case there are any violations noticed by the inspector, in case there is a problem with the quality of the medicine, or in case regulatory authorities notify about any problems, it should be intimated within seven days. In case of violations, this approval can be immediately suspended or revoked.
The elimination of taxes on medicines and medical devices will make Indian generic medicines more affordable and competitive in Europe. Furthermore, administrative costs will be reduced and the process for obtaining drug approvals in Europe will be faster due to simplified regulations.
Companies that have received approval to export APIs to the European Union include Honor Labs Limited (Telangana), Ravi Biolife Private Limited (Maharashtra), and Unimax Chemicals Private Limited (Maharashtra).
